Research programme: autoimmune diseases - Sareum/SRI International

Drug Profile

Research programme: autoimmune diseases - Sareum/SRI International

Alternative Names: SAR-20347; SAR-T29; SAR-T33; SAR-T38

Latest Information Update: 27 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sareum
  • Developer Sareum; SRI International
  • Class Small molecules
  • Mechanism of Action TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Autoimmune disorders; Rheumatoid arthritis

Most Recent Events

  • 29 Nov 2016 Preclinical trials in Acute lymphoblastic leukaemia in United Kingdom (PO)
  • 25 Jul 2016 Research programme: autoimmune diseases - Sareum/SRI International is available for licensing -http://www.sareum.com/files/6214/6045/0916/Sareum_SKIL_TYK2_Mar16.pdf
  • 25 Jul 2016 Preclinical trials in Autoimmune disorders in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top